作者: Shiv Singh , Marie Christin Hasselluhn , Albrecht Neesse , None
DOI: 10.1136/GUTJNL-2018-318086
关键词:
摘要: Pancreatic ductal adenocarcinoma (PDAC) constitutes the most common malignancy of pancreas. With a 5-year survival rate below 10% and median less than 12 months following diagnosis, PDAC remains major biomedical challenge. Due to lack early symptoms patients are usually diagnosed with locally advanced or metastatic disease where surgical removal tumour is no longer feasible. Despite some recent developments in medical oncology, response chemotherapeutic regimens such as nab-paclitaxel FOLFIRINOX limited accompanied by side effects nausea, neutropenia, neuropathy infectious complications.1 Histologically, majority cases characterised tubular glands embedded pronounced microenvironment (TME) composed acellular components collagen, hyaluronic acid, fibronectin abundant matricellular proteins. Moreover, inflammatory cells tumour-associated macrophages, neutrophils, regulatory T cells, cancer-associated fibroblasts neural accumulate around neoplastic actively contribute TME formation tumour-stroma crosstalk.2 Notably, histopathological features have not yet been used to select therapeutic strategies. However, increasing evidence from other entities breast, melanoma, lung colon cancer suggest that molecular characteristics can vastly differ microscopically indistinguishable cancers. advent high-throughput sequencing technologies whole-genome profiling transcriptome profiling, taxonomy cancers has become …